BioVersys and GSK have expanded their strategic collaboration to accelerate Alpibectir’s (BVL-GSK098; Small molecule) development. Beyond the present P-IIa, both companies will continue to develop Alpibectir in TB pulmonary and TB meningitis
Under the collaboration, GSK will participate in BioVersys’ Series C extension with equity investment. Addition of CHF 12.3M from existing and new investors, results in total of CHF 44.9M in Series C round
Additional funding will support clinical development of BioVersys’ portfolio includes BV100, a hospital antibiotic targeting Acinetobacter baumannii
Ref: BioVersys | Image: BioVersys
Related News:- GSK to Highlight Results from the P-III (EAGLE-1) Study of Gepotidacin for Treating Uncomplicated Urogenital Gonorrhoea (GC) at ESCMID 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
